This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.
- Investigator
- Ali Ataya
- Ages
- 18 Years - 99 Years
- Sexes
- All
Clinical trials
-
Sapphire -
1305-0023 (FIBRONEERTM ILD) This study is open to adults with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). People who have a form of PF-ILD other than Idiopathic Pulmonary Fibrosis (IPF) can join the study. If they already take nintedanib, they can continue鈥�
- Investigators
- Christopher Harden, Divya C Patel
- Ages
- 18 Years - N/A
- Sexes
- All